布地奈德/福莫特罗吸入剂对老年COPD稳定期患者生活质量的影响

Effect on quality-of-life (QOL) of budesonide/fomoterol in single inhaler in the treatment of old patients with stable moderate to severe chronic obstructive pulmonary disease

目的探讨布地奈德/福莫特罗吸入剂吸入治疗对老年COPD稳定期患者生活质量的影响。方法确诊COPD老年患者共36例,分为治疗组16例,对照组20例,治疗组予以布地奈德/福莫特罗吸入剂吸入治疗,对照组不进行特殊治疗,疗程6个月,观察肺功能、6-MWT、SF-36生活质量调查表的得分对比变化。结果治疗组肺功能、6-MWT与对照组比较均有好转(P<0.05),治疗组SF-36生活质量调查表的躯体功能,躯体角色,健康总体自评,生命活力,肌体疼痛、社会功能等6个方面得分高于治疗前(P<0.05)且与对照组比较有改善(P<0.05)。而情感角色和心理健康2个方面与在治疗前相比差别无统计学意义(P>0.05)。结论布地奈德/福莫特罗吸入剂吸入治疗是老年COPD患者稳定期有效的治疗方案,长期吸入治疗能延缓其肺功能的损害,提高生活质量、增加运动耐量。

Objective To investigate the effect on quality-of-life （QOL） of budesonide/fomoterol in single inhaler in the treatment of old patients with stable moderate to severe chronic obstructive pulmonary disease （COPD）. Methods 36 patients （ age ≥ 60 ） with COPD were divided into trial and control groups. Baseline treatments were similar in all patients. Patients in the trial group received budesonide/fomoterol （ 160/4. 5 μg） inhalation twice daily via turbuhaler for 6 months. The control group didn＇t receive special treatment. Results The lung function, 6-MWT of the COPD patients improved after having received budesonide/fomoterol inhalation （ P 〈 0. 05 ）. The scores on five aspects of SF-36 which included physical functioning, physical role, body pain, general health, vitality and social functional were better in the treatment group than those in the control group （ except for emotional role and mental health）. Conclusion The budesonide/fomoterol in single inhaler in the treatment improves health-related quality of life, meets the requirement of life in the elderly patients with stable moderate to severe chronic obstructive pulmonary disease （COPD）.